HCP’s Neutral Rating Reaffirmed at Zacks (HCP)
HCP (NYSE:HCP)‘s stock had its “neutral” rating reiterated by Zacks in a note issued to investors on Monday. They currently have a $44.00 target price on the stock. Zacks‘s price target indicates a potential upside of 4.66% from the stock’s previous close.
Zacks’ analyst wrote, “Aided by growth in revenues, HCP’s first quarter 2014 adjusted FFO per share came a penny ahead of both the Zacks Consensus Estimate as well as the year-ago quarter figure. Improving fundamentals in the healthcare REIT market, a well-balanced, diversified portfolio, decent balance sheet, opportunistic acquisitions and strategic tie ups place HCP on the growth trajectory. In particular, the CCRC partnership with Brookdale offers a solid platform for growth. However, cut-throat competition and dependency on governmental healthcare programs for a number of its tenants and operators remains a headwind. This is because in the recent years governmental payors have reduced payments to healthcare providers due to budgetary pressures.”
Shares of HCP (NYSE:HCP) traded up 0.69% on Monday, hitting $42.04. The stock had a trading volume of 2,796,857 shares. HCP has a 1-year low of $35.50 and a 1-year high of $48.23. The stock’s 50-day moving average is $41.70 and its 200-day moving average is $38.7. The company has a market cap of $19.263 billion and a P/E ratio of 19.09.
HCP (NYSE:HCP) last announced its earnings results on Tuesday, May 6th. The company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.01. The company had revenue of $530.00 million for the quarter, compared to the consensus estimate of $518.87 million. During the same quarter in the previous year, the company posted $0.74 earnings per share. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts predict that HCP will post $3.03 earnings per share for the current fiscal year.
HCP has been the subject of a number of other recent research reports. Analysts at RBC Capital raised their price target on shares of HCP from $38.00 to $40.00 in a research note on Monday, May 12th. Analysts at Citigroup Inc. reiterated an “equal weight” rating on shares of HCP in a research note on Wednesday, May 7th. They now have a $42.00 price target on the stock, up previously from $39.00. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $43.00.
HCP, Inc (NYSE:HCP) is a real estate investment trust (REIT).
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.